Transforming medical devices for improved patient outcomes

DESSOLVE China

clinical-china

DESSOLVE China is a prospective, single-blind, multi-center, randomized, controlled, registration clinical trial on the efficacy and safety of sirolimus-eluting stent (MiStent® System) in the treatment of patients with coronary heart disease comparing angiographic measures at nine months and clinical outcomes at 12 months. The trial will enroll 428 patients in a 1:1 ratio (214 cases enrolled into each group, MiStent and the control, TIVOLI) in up to 23 clinical sites.

Principal Investigators:
Prof. Yaling Han, General Hospital, Shenyang Military Region, Shenyang, China
Prof. Yuejin Yang, Cardiovascular Institute / Fu Wai Hospital, Beijing, China (co-principal investigator)
Prof. Xu Bo, Cardiovascular Institute / Fu Wai Hospital, Beijing, China (co-principal investigator)

More information on the DESSOLVE C trial can be found here.